line_item,period,value,symbol
Tax Effect Of Unusual Items,2025-03-31 00:00:00,0.0,AJANTPHARM.NS
Tax Rate For Calcs,2025-03-31 00:00:00,0.226017,AJANTPHARM.NS
Normalized EBITDA,2025-03-31 00:00:00,13540000000.0,AJANTPHARM.NS
Total Unusual Items,2025-03-31 00:00:00,,AJANTPHARM.NS
Total Unusual Items Excluding Goodwill,2025-03-31 00:00:00,,AJANTPHARM.NS
Net Income From Continuing Operation Net Minority Interest,2025-03-31 00:00:00,9203900000.0,AJANTPHARM.NS
Reconciled Depreciation,2025-03-31 00:00:00,1441100000.0,AJANTPHARM.NS
Reconciled Cost Of Revenue,2025-03-31 00:00:00,10707600000.0,AJANTPHARM.NS
EBITDA,2025-03-31 00:00:00,13540000000.0,AJANTPHARM.NS
EBIT,2025-03-31 00:00:00,12098900000.0,AJANTPHARM.NS
Net Interest Income,2025-03-31 00:00:00,-207300000.0,AJANTPHARM.NS
Interest Expense,2025-03-31 00:00:00,207300000.0,AJANTPHARM.NS
Interest Income,2025-03-31 00:00:00,,AJANTPHARM.NS
Normalized Income,2025-03-31 00:00:00,9203900000.0,AJANTPHARM.NS
Net Income From Continuing And Discontinued Operation,2025-03-31 00:00:00,9203900000.0,AJANTPHARM.NS
Total Expenses,2025-03-31 00:00:00,23045600000.0,AJANTPHARM.NS
Rent Expense Supplemental,2025-03-31 00:00:00,,AJANTPHARM.NS
Diluted Average Shares,2025-03-31 00:00:00,125172039.0,AJANTPHARM.NS
Basic Average Shares,2025-03-31 00:00:00,125120990.0,AJANTPHARM.NS
Diluted EPS,2025-03-31 00:00:00,73.53,AJANTPHARM.NS
Basic EPS,2025-03-31 00:00:00,73.56,AJANTPHARM.NS
Diluted NI Availto Com Stockholders,2025-03-31 00:00:00,9203900000.0,AJANTPHARM.NS
Average Dilution Earnings,2025-03-31 00:00:00,,AJANTPHARM.NS
Net Income Common Stockholders,2025-03-31 00:00:00,9203900000.0,AJANTPHARM.NS
Otherunder Preferred Stock Dividend,2025-03-31 00:00:00,0.0,AJANTPHARM.NS
Net Income,2025-03-31 00:00:00,9203900000.0,AJANTPHARM.NS
Net Income Including Noncontrolling Interests,2025-03-31 00:00:00,9203900000.0,AJANTPHARM.NS
Net Income Continuous Operations,2025-03-31 00:00:00,9203900000.0,AJANTPHARM.NS
Tax Provision,2025-03-31 00:00:00,2687700000.0,AJANTPHARM.NS
Pretax Income,2025-03-31 00:00:00,11891600000.0,AJANTPHARM.NS
Other Non Operating Income Expenses,2025-03-31 00:00:00,-11530400000.0,AJANTPHARM.NS
Special Income Charges,2025-03-31 00:00:00,,AJANTPHARM.NS
Other Special Charges,2025-03-31 00:00:00,,AJANTPHARM.NS
Write Off,2025-03-31 00:00:00,,AJANTPHARM.NS
Impairment Of Capital Assets,2025-03-31 00:00:00,,AJANTPHARM.NS
Net Non Operating Interest Income Expense,2025-03-31 00:00:00,-207300000.0,AJANTPHARM.NS
Interest Expense Non Operating,2025-03-31 00:00:00,207300000.0,AJANTPHARM.NS
Interest Income Non Operating,2025-03-31 00:00:00,,AJANTPHARM.NS
Operating Income,2025-03-31 00:00:00,23435400000.0,AJANTPHARM.NS
Operating Expense,2025-03-31 00:00:00,12338000000.0,AJANTPHARM.NS
Other Operating Expenses,2025-03-31 00:00:00,,AJANTPHARM.NS
Depreciation And Amortization In Income Statement,2025-03-31 00:00:00,1441100000.0,AJANTPHARM.NS
Amortization,2025-03-31 00:00:00,,AJANTPHARM.NS
Depreciation Income Statement,2025-03-31 00:00:00,1441100000.0,AJANTPHARM.NS
Selling General And Administration,2025-03-31 00:00:00,,AJANTPHARM.NS
Selling And Marketing Expense,2025-03-31 00:00:00,,AJANTPHARM.NS
General And Administrative Expense,2025-03-31 00:00:00,,AJANTPHARM.NS
Rent And Landing Fees,2025-03-31 00:00:00,,AJANTPHARM.NS
Gross Profit,2025-03-31 00:00:00,35773400000.0,AJANTPHARM.NS
Cost Of Revenue,2025-03-31 00:00:00,10707600000.0,AJANTPHARM.NS
Total Revenue,2025-03-31 00:00:00,46481000000.0,AJANTPHARM.NS
Operating Revenue,2025-03-31 00:00:00,46481000000.0,AJANTPHARM.NS
Tax Effect Of Unusual Items,2024-03-31 00:00:00,0.0,AJANTPHARM.NS
Tax Rate For Calcs,2024-03-31 00:00:00,0.267306,AJANTPHARM.NS
Normalized EBITDA,2024-03-31 00:00:00,12565400000.0,AJANTPHARM.NS
Total Unusual Items,2024-03-31 00:00:00,283200000.0,AJANTPHARM.NS
Total Unusual Items Excluding Goodwill,2024-03-31 00:00:00,283200000.0,AJANTPHARM.NS
Net Income From Continuing Operation Net Minority Interest,2024-03-31 00:00:00,8161700000.0,AJANTPHARM.NS
Reconciled Depreciation,2024-03-31 00:00:00,1354000000.0,AJANTPHARM.NS
Reconciled Cost Of Revenue,2024-03-31 00:00:00,10665700000.0,AJANTPHARM.NS
EBITDA,2024-03-31 00:00:00,12565400000.0,AJANTPHARM.NS
EBIT,2024-03-31 00:00:00,11211400000.0,AJANTPHARM.NS
Net Interest Income,2024-03-31 00:00:00,-72100000.0,AJANTPHARM.NS
Interest Expense,2024-03-31 00:00:00,72100000.0,AJANTPHARM.NS
Interest Income,2024-03-31 00:00:00,277100000.0,AJANTPHARM.NS
Normalized Income,2024-03-31 00:00:00,8161700000.0,AJANTPHARM.NS
Net Income From Continuing And Discontinued Operation,2024-03-31 00:00:00,8161700000.0,AJANTPHARM.NS
Total Expenses,2024-03-31 00:00:00,21023100000.0,AJANTPHARM.NS
Rent Expense Supplemental,2024-03-31 00:00:00,73800000.0,AJANTPHARM.NS
Diluted Average Shares,2024-03-31 00:00:00,126010499.0,AJANTPHARM.NS
Basic Average Shares,2024-03-31 00:00:00,125913298.0,AJANTPHARM.NS
Diluted EPS,2024-03-31 00:00:00,64.77,AJANTPHARM.NS
Basic EPS,2024-03-31 00:00:00,64.82,AJANTPHARM.NS
Diluted NI Availto Com Stockholders,2024-03-31 00:00:00,8161700000.0,AJANTPHARM.NS
Average Dilution Earnings,2024-03-31 00:00:00,0.0,AJANTPHARM.NS
Net Income Common Stockholders,2024-03-31 00:00:00,8161700000.0,AJANTPHARM.NS
Otherunder Preferred Stock Dividend,2024-03-31 00:00:00,0.0,AJANTPHARM.NS
Net Income,2024-03-31 00:00:00,8161700000.0,AJANTPHARM.NS
Net Income Including Noncontrolling Interests,2024-03-31 00:00:00,8161700000.0,AJANTPHARM.NS
Net Income Continuous Operations,2024-03-31 00:00:00,8161700000.0,AJANTPHARM.NS
Tax Provision,2024-03-31 00:00:00,2977600000.0,AJANTPHARM.NS
Pretax Income,2024-03-31 00:00:00,11139300000.0,AJANTPHARM.NS
Other Non Operating Income Expenses,2024-03-31 00:00:00,-10239500000.0,AJANTPHARM.NS
Special Income Charges,2024-03-31 00:00:00,34900000.0,AJANTPHARM.NS
Other Special Charges,2024-03-31 00:00:00,-34900000.0,AJANTPHARM.NS
Write Off,2024-03-31 00:00:00,,AJANTPHARM.NS
Impairment Of Capital Assets,2024-03-31 00:00:00,,AJANTPHARM.NS
Net Non Operating Interest Income Expense,2024-03-31 00:00:00,-72100000.0,AJANTPHARM.NS
Interest Expense Non Operating,2024-03-31 00:00:00,72100000.0,AJANTPHARM.NS
Interest Income Non Operating,2024-03-31 00:00:00,277100000.0,AJANTPHARM.NS
Operating Income,2024-03-31 00:00:00,21064000000.0,AJANTPHARM.NS
Operating Expense,2024-03-31 00:00:00,10357400000.0,AJANTPHARM.NS
Other Operating Expenses,2024-03-31 00:00:00,6214800000.0,AJANTPHARM.NS
Depreciation And Amortization In Income Statement,2024-03-31 00:00:00,1354000000.0,AJANTPHARM.NS
Amortization,2024-03-31 00:00:00,50100000.0,AJANTPHARM.NS
Depreciation Income Statement,2024-03-31 00:00:00,1354000000.0,AJANTPHARM.NS
Selling General And Administration,2024-03-31 00:00:00,3826600000.0,AJANTPHARM.NS
Selling And Marketing Expense,2024-03-31 00:00:00,2531200000.0,AJANTPHARM.NS
General And Administrative Expense,2024-03-31 00:00:00,1295400000.0,AJANTPHARM.NS
Rent And Landing Fees,2024-03-31 00:00:00,73800000.0,AJANTPHARM.NS
Gross Profit,2024-03-31 00:00:00,31421400000.0,AJANTPHARM.NS
Cost Of Revenue,2024-03-31 00:00:00,10665700000.0,AJANTPHARM.NS
Total Revenue,2024-03-31 00:00:00,42087100000.0,AJANTPHARM.NS
Operating Revenue,2024-03-31 00:00:00,42087100000.0,AJANTPHARM.NS
Tax Effect Of Unusual Items,2023-03-31 00:00:00,-19728500.0,AJANTPHARM.NS
Tax Rate For Calcs,2023-03-31 00:00:00,0.211,AJANTPHARM.NS
Normalized EBITDA,2023-03-31 00:00:00,8912400000.0,AJANTPHARM.NS
Total Unusual Items,2023-03-31 00:00:00,-93500000.0,AJANTPHARM.NS
Total Unusual Items Excluding Goodwill,2023-03-31 00:00:00,-93500000.0,AJANTPHARM.NS
Net Income From Continuing Operation Net Minority Interest,2023-03-31 00:00:00,5879800000.0,AJANTPHARM.NS
Reconciled Depreciation,2023-03-31 00:00:00,1308000000.0,AJANTPHARM.NS
Reconciled Cost Of Revenue,2023-03-31 00:00:00,11167300000.0,AJANTPHARM.NS
EBITDA,2023-03-31 00:00:00,8818900000.0,AJANTPHARM.NS
EBIT,2023-03-31 00:00:00,7510900000.0,AJANTPHARM.NS
Net Interest Income,2023-03-31 00:00:00,26200000.0,AJANTPHARM.NS
Interest Expense,2023-03-31 00:00:00,58400000.0,AJANTPHARM.NS
Interest Income,2023-03-31 00:00:00,84600000.0,AJANTPHARM.NS
Normalized Income,2023-03-31 00:00:00,5953571500.0,AJANTPHARM.NS
Net Income From Continuing And Discontinued Operation,2023-03-31 00:00:00,5879800000.0,AJANTPHARM.NS
Total Expenses,2023-03-31 00:00:00,30277600000.0,AJANTPHARM.NS
Rent Expense Supplemental,2023-03-31 00:00:00,75900000.0,AJANTPHARM.NS
Diluted Average Shares,2023-03-31 00:00:00,128122871.0,AJANTPHARM.NS
Basic Average Shares,2023-03-31 00:00:00,128118877.0,AJANTPHARM.NS
Diluted EPS,2023-03-31 00:00:00,45.89,AJANTPHARM.NS
Basic EPS,2023-03-31 00:00:00,45.89,AJANTPHARM.NS
Diluted NI Availto Com Stockholders,2023-03-31 00:00:00,5879800000.0,AJANTPHARM.NS
Average Dilution Earnings,2023-03-31 00:00:00,0.0,AJANTPHARM.NS
Net Income Common Stockholders,2023-03-31 00:00:00,5879800000.0,AJANTPHARM.NS
Otherunder Preferred Stock Dividend,2023-03-31 00:00:00,0.0,AJANTPHARM.NS
Net Income,2023-03-31 00:00:00,5879800000.0,AJANTPHARM.NS
Net Income Including Noncontrolling Interests,2023-03-31 00:00:00,5879800000.0,AJANTPHARM.NS
Net Income Continuous Operations,2023-03-31 00:00:00,5879800000.0,AJANTPHARM.NS
Tax Provision,2023-03-31 00:00:00,1572700000.0,AJANTPHARM.NS
Pretax Income,2023-03-31 00:00:00,7452500000.0,AJANTPHARM.NS
Other Non Operating Income Expenses,2023-03-31 00:00:00,61500000.0,AJANTPHARM.NS
Special Income Charges,2023-03-31 00:00:00,-53500000.0,AJANTPHARM.NS
Other Special Charges,2023-03-31 00:00:00,53500000.0,AJANTPHARM.NS
Write Off,2023-03-31 00:00:00,-8400000.0,AJANTPHARM.NS
Impairment Of Capital Assets,2023-03-31 00:00:00,200000.0,AJANTPHARM.NS
Net Non Operating Interest Income Expense,2023-03-31 00:00:00,26200000.0,AJANTPHARM.NS
Interest Expense Non Operating,2023-03-31 00:00:00,58400000.0,AJANTPHARM.NS
Interest Income Non Operating,2023-03-31 00:00:00,84600000.0,AJANTPHARM.NS
Operating Income,2023-03-31 00:00:00,6797600000.0,AJANTPHARM.NS
Operating Expense,2023-03-31 00:00:00,19110300000.0,AJANTPHARM.NS
Other Operating Expenses,2023-03-31 00:00:00,6729000000.0,AJANTPHARM.NS
Depreciation And Amortization In Income Statement,2023-03-31 00:00:00,1308000000.0,AJANTPHARM.NS
Amortization,2023-03-31 00:00:00,41000000.0,AJANTPHARM.NS
Depreciation Income Statement,2023-03-31 00:00:00,1267000000.0,AJANTPHARM.NS
Selling General And Administration,2023-03-31 00:00:00,3426800000.0,AJANTPHARM.NS
Selling And Marketing Expense,2023-03-31 00:00:00,2267100000.0,AJANTPHARM.NS
General And Administrative Expense,2023-03-31 00:00:00,1159700000.0,AJANTPHARM.NS
Rent And Landing Fees,2023-03-31 00:00:00,75900000.0,AJANTPHARM.NS
Gross Profit,2023-03-31 00:00:00,25907900000.0,AJANTPHARM.NS
Cost Of Revenue,2023-03-31 00:00:00,11167300000.0,AJANTPHARM.NS
Total Revenue,2023-03-31 00:00:00,37075200000.0,AJANTPHARM.NS
Operating Revenue,2023-03-31 00:00:00,37075200000.0,AJANTPHARM.NS
Tax Effect Of Unusual Items,2022-03-31 00:00:00,46569280.0,AJANTPHARM.NS
Tax Rate For Calcs,2022-03-31 00:00:00,0.2164,AJANTPHARM.NS
Normalized EBITDA,2022-03-31 00:00:00,10234600000.0,AJANTPHARM.NS
Total Unusual Items,2022-03-31 00:00:00,215200000.0,AJANTPHARM.NS
Total Unusual Items Excluding Goodwill,2022-03-31 00:00:00,215200000.0,AJANTPHARM.NS
Net Income From Continuing Operation Net Minority Interest,2022-03-31 00:00:00,7126800000.0,AJANTPHARM.NS
Reconciled Depreciation,2022-03-31 00:00:00,1253000000.0,AJANTPHARM.NS
Reconciled Cost Of Revenue,2022-03-31 00:00:00,8867200000.0,AJANTPHARM.NS
EBITDA,2022-03-31 00:00:00,10449800000.0,AJANTPHARM.NS
EBIT,2022-03-31 00:00:00,9196800000.0,AJANTPHARM.NS
Net Interest Income,2022-03-31 00:00:00,44500000.0,AJANTPHARM.NS
Interest Expense,2022-03-31 00:00:00,102000000.0,AJANTPHARM.NS
Interest Income,2022-03-31 00:00:00,146500000.0,AJANTPHARM.NS
Normalized Income,2022-03-31 00:00:00,6958169280.0,AJANTPHARM.NS
Net Income From Continuing And Discontinued Operation,2022-03-31 00:00:00,7126800000.0,AJANTPHARM.NS
Total Expenses,2022-03-31 00:00:00,24722500000.0,AJANTPHARM.NS
Rent Expense Supplemental,2022-03-31 00:00:00,65400000.0,AJANTPHARM.NS
Diluted Average Shares,2022-03-31 00:00:00,129662555.0,AJANTPHARM.NS
Basic Average Shares,2022-03-31 00:00:00,129658060.0,AJANTPHARM.NS
Diluted EPS,2022-03-31 00:00:00,54.96,AJANTPHARM.NS
Basic EPS,2022-03-31 00:00:00,54.97,AJANTPHARM.NS
Diluted NI Availto Com Stockholders,2022-03-31 00:00:00,7126800000.0,AJANTPHARM.NS
Average Dilution Earnings,2022-03-31 00:00:00,,AJANTPHARM.NS
Net Income Common Stockholders,2022-03-31 00:00:00,7126800000.0,AJANTPHARM.NS
Otherunder Preferred Stock Dividend,2022-03-31 00:00:00,0.0,AJANTPHARM.NS
Net Income,2022-03-31 00:00:00,7126800000.0,AJANTPHARM.NS
Net Income Including Noncontrolling Interests,2022-03-31 00:00:00,7126800000.0,AJANTPHARM.NS
Net Income Continuous Operations,2022-03-31 00:00:00,7126800000.0,AJANTPHARM.NS
Tax Provision,2022-03-31 00:00:00,1968000000.0,AJANTPHARM.NS
Pretax Income,2022-03-31 00:00:00,9094800000.0,AJANTPHARM.NS
Other Non Operating Income Expenses,2022-03-31 00:00:00,152900000.0,AJANTPHARM.NS
Special Income Charges,2022-03-31 00:00:00,-78500000.0,AJANTPHARM.NS
Other Special Charges,2022-03-31 00:00:00,38700000.0,AJANTPHARM.NS
Write Off,2022-03-31 00:00:00,0.0,AJANTPHARM.NS
Impairment Of Capital Assets,2022-03-31 00:00:00,39800000.0,AJANTPHARM.NS
Net Non Operating Interest Income Expense,2022-03-31 00:00:00,44500000.0,AJANTPHARM.NS
Interest Expense Non Operating,2022-03-31 00:00:00,102000000.0,AJANTPHARM.NS
Interest Income Non Operating,2022-03-31 00:00:00,146500000.0,AJANTPHARM.NS
Operating Income,2022-03-31 00:00:00,8118800000.0,AJANTPHARM.NS
Operating Expense,2022-03-31 00:00:00,15855300000.0,AJANTPHARM.NS
Other Operating Expenses,2022-03-31 00:00:00,5401800000.0,AJANTPHARM.NS
Depreciation And Amortization In Income Statement,2022-03-31 00:00:00,1252900000.0,AJANTPHARM.NS
Amortization,2022-03-31 00:00:00,39400000.0,AJANTPHARM.NS
Depreciation Income Statement,2022-03-31 00:00:00,1213500000.0,AJANTPHARM.NS
Selling General And Administration,2022-03-31 00:00:00,3137200000.0,AJANTPHARM.NS
Selling And Marketing Expense,2022-03-31 00:00:00,2185700000.0,AJANTPHARM.NS
General And Administrative Expense,2022-03-31 00:00:00,951500000.0,AJANTPHARM.NS
Rent And Landing Fees,2022-03-31 00:00:00,65400000.0,AJANTPHARM.NS
Gross Profit,2022-03-31 00:00:00,23974100000.0,AJANTPHARM.NS
Cost Of Revenue,2022-03-31 00:00:00,8867200000.0,AJANTPHARM.NS
Total Revenue,2022-03-31 00:00:00,32841300000.0,AJANTPHARM.NS
Operating Revenue,2022-03-31 00:00:00,32841300000.0,AJANTPHARM.NS
Tax Effect Of Unusual Items,2021-03-31 00:00:00,,AJANTPHARM.NS
Tax Rate For Calcs,2021-03-31 00:00:00,,AJANTPHARM.NS
Normalized EBITDA,2021-03-31 00:00:00,,AJANTPHARM.NS
Total Unusual Items,2021-03-31 00:00:00,25900000.0,AJANTPHARM.NS
Total Unusual Items Excluding Goodwill,2021-03-31 00:00:00,25900000.0,AJANTPHARM.NS
Net Income From Continuing Operation Net Minority Interest,2021-03-31 00:00:00,,AJANTPHARM.NS
Reconciled Depreciation,2021-03-31 00:00:00,,AJANTPHARM.NS
Reconciled Cost Of Revenue,2021-03-31 00:00:00,,AJANTPHARM.NS
EBITDA,2021-03-31 00:00:00,,AJANTPHARM.NS
EBIT,2021-03-31 00:00:00,,AJANTPHARM.NS
Net Interest Income,2021-03-31 00:00:00,,AJANTPHARM.NS
Interest Expense,2021-03-31 00:00:00,,AJANTPHARM.NS
Interest Income,2021-03-31 00:00:00,35100000.0,AJANTPHARM.NS
Normalized Income,2021-03-31 00:00:00,,AJANTPHARM.NS
Net Income From Continuing And Discontinued Operation,2021-03-31 00:00:00,,AJANTPHARM.NS
Total Expenses,2021-03-31 00:00:00,,AJANTPHARM.NS
Rent Expense Supplemental,2021-03-31 00:00:00,24300000.0,AJANTPHARM.NS
Diluted Average Shares,2021-03-31 00:00:00,,AJANTPHARM.NS
Basic Average Shares,2021-03-31 00:00:00,,AJANTPHARM.NS
Diluted EPS,2021-03-31 00:00:00,,AJANTPHARM.NS
Basic EPS,2021-03-31 00:00:00,,AJANTPHARM.NS
Diluted NI Availto Com Stockholders,2021-03-31 00:00:00,,AJANTPHARM.NS
Average Dilution Earnings,2021-03-31 00:00:00,0.0,AJANTPHARM.NS
Net Income Common Stockholders,2021-03-31 00:00:00,,AJANTPHARM.NS
Otherunder Preferred Stock Dividend,2021-03-31 00:00:00,,AJANTPHARM.NS
Net Income,2021-03-31 00:00:00,,AJANTPHARM.NS
Net Income Including Noncontrolling Interests,2021-03-31 00:00:00,,AJANTPHARM.NS
Net Income Continuous Operations,2021-03-31 00:00:00,,AJANTPHARM.NS
Tax Provision,2021-03-31 00:00:00,,AJANTPHARM.NS
Pretax Income,2021-03-31 00:00:00,,AJANTPHARM.NS
Other Non Operating Income Expenses,2021-03-31 00:00:00,,AJANTPHARM.NS
Special Income Charges,2021-03-31 00:00:00,-97700000.0,AJANTPHARM.NS
Other Special Charges,2021-03-31 00:00:00,22100000.0,AJANTPHARM.NS
Write Off,2021-03-31 00:00:00,,AJANTPHARM.NS
Impairment Of Capital Assets,2021-03-31 00:00:00,75600000.0,AJANTPHARM.NS
Net Non Operating Interest Income Expense,2021-03-31 00:00:00,,AJANTPHARM.NS
Interest Expense Non Operating,2021-03-31 00:00:00,,AJANTPHARM.NS
Interest Income Non Operating,2021-03-31 00:00:00,35100000.0,AJANTPHARM.NS
Operating Income,2021-03-31 00:00:00,,AJANTPHARM.NS
Operating Expense,2021-03-31 00:00:00,,AJANTPHARM.NS
Other Operating Expenses,2021-03-31 00:00:00,3646200000.0,AJANTPHARM.NS
Depreciation And Amortization In Income Statement,2021-03-31 00:00:00,,AJANTPHARM.NS
Amortization,2021-03-31 00:00:00,46900000.0,AJANTPHARM.NS
Depreciation Income Statement,2021-03-31 00:00:00,,AJANTPHARM.NS
Selling General And Administration,2021-03-31 00:00:00,2768100000.0,AJANTPHARM.NS
Selling And Marketing Expense,2021-03-31 00:00:00,2384100000.0,AJANTPHARM.NS
General And Administrative Expense,2021-03-31 00:00:00,384000000.0,AJANTPHARM.NS
Rent And Landing Fees,2021-03-31 00:00:00,24300000.0,AJANTPHARM.NS
Gross Profit,2021-03-31 00:00:00,,AJANTPHARM.NS
Cost Of Revenue,2021-03-31 00:00:00,,AJANTPHARM.NS
Total Revenue,2021-03-31 00:00:00,,AJANTPHARM.NS
Operating Revenue,2021-03-31 00:00:00,,AJANTPHARM.NS
